Version 1
: Received: 18 January 2022 / Approved: 20 January 2022 / Online: 20 January 2022 (09:46:30 CET)
Version 2
: Received: 21 January 2022 / Approved: 24 January 2022 / Online: 24 January 2022 (10:53:36 CET)
How to cite:
Torres-Romero, J.C.; Barros-Romo, A.; de Souza Cavalcante, M.; Monteiro-Moreira, A.C.; Pinto Lobo, M.D.; Feitosa Pinheiro, R.; Moreira, R.; Sepúlveda-Casadiego, Y. Frutalin Affinity Chromatography on Sepharose Gel as a Strategy for the Identification of Possible Tumor Markers in Myelodysplastic Syndromes. Preprints2022, 2022010292. https://doi.org/10.20944/preprints202201.0292.v1
Torres-Romero, J.C.; Barros-Romo, A.; de Souza Cavalcante, M.; Monteiro-Moreira, A.C.; Pinto Lobo, M.D.; Feitosa Pinheiro, R.; Moreira, R.; Sepúlveda-Casadiego, Y. Frutalin Affinity Chromatography on Sepharose Gel as a Strategy for the Identification of Possible Tumor Markers in Myelodysplastic Syndromes. Preprints 2022, 2022010292. https://doi.org/10.20944/preprints202201.0292.v1
Torres-Romero, J.C.; Barros-Romo, A.; de Souza Cavalcante, M.; Monteiro-Moreira, A.C.; Pinto Lobo, M.D.; Feitosa Pinheiro, R.; Moreira, R.; Sepúlveda-Casadiego, Y. Frutalin Affinity Chromatography on Sepharose Gel as a Strategy for the Identification of Possible Tumor Markers in Myelodysplastic Syndromes. Preprints2022, 2022010292. https://doi.org/10.20944/preprints202201.0292.v1
APA Style
Torres-Romero, J.C., Barros-Romo, A., de Souza Cavalcante, M., Monteiro-Moreira, A.C., Pinto Lobo, M.D., Feitosa Pinheiro, R., Moreira, R., & Sepúlveda-Casadiego, Y. (2022). Frutalin Affinity Chromatography on Sepharose Gel as a Strategy for the Identification of Possible Tumor Markers in Myelodysplastic Syndromes. Preprints. https://doi.org/10.20944/preprints202201.0292.v1
Chicago/Turabian Style
Torres-Romero, J.C., Renato Moreira and Yulian Sepúlveda-Casadiego. 2022 "Frutalin Affinity Chromatography on Sepharose Gel as a Strategy for the Identification of Possible Tumor Markers in Myelodysplastic Syndromes" Preprints. https://doi.org/10.20944/preprints202201.0292.v1
Abstract
Myelodysplastic syndromes (MDS) are diseases that occur when blood-producing cells in the bone marrow are damaged; such damage can affect one or more types of blood cells. Common types of MDS are refractory anemia with ring sideroblasts and refractory anemia with excess blasts (MDS-RS and MDS-EB, respectively). This work analyzed the proteomics of the medullary plasma of 10 patients with MDS-RS and MDS-EB compared to healthy control people. Overexpressed proteins that may be potential candidates for biological markers for the evaluation, study, and diagnosis of these diseases have been identified. These samples were subjected to immunodepleting, concentrated, and digested for further analysis by mass spectrometry. The ratios between selected groups and healthy people were calculated. Seven overexpressed proteins in both syndromes were identified as potential biomarker candidates: vitronectin (VTN), (2) fibrinogen (FGA), (3) pregnancy zone protein (PZP), (4) kininogen (KNG1), (5) immunoglobulin lambda chain (IGLL1), (6) complement factor C4b, and (7) hemopexin (HPX). A modified affinity chromatographic column with lectin frutalin (FTL) was used for non-depleted samples. Immunoglobulin M (IgM) was expressed in the samples from both syndromes. Surprisingly, IgM from patients with syndromes was over retained on the frutalin (FTL) column when compared with the control group. We further hypothesized that over retention of this protein by the FTL is due to the presence of α-galactosidic residues in the IgM of MDS-RS and MDS-EB patients. Differential recognition of proteins on non-depleted samples from the use of FTL appears to be a powerful tool for proteomic analysis.
Keywords
Cancer biomarker; Proteomic analysis; Myelodysplastic syndromes; Frutalin; MDS-RS; MDS-EB
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
